MG
CRNX

Marex Group’s Crinetics Pharmaceuticals CRNX Stock Holding History

Marex Group’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$348K Buy
9,300
+2,797
+43% +$104K ﹤0.01% 809
2026
Q1 		$236K Buy
+6,503
New +$290K ﹤0.01% 852

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marex Group's CRNX Position: Q2 2026 in Review

Marex Group increased its Crinetics Pharmaceuticals (CRNX) stake by 43% in Q2 2026, buying an estimated $104K and bringing the position to 9,300 shares worth $348K. The position accounts for ﹤0.01% of the portfolio, ranked #809.

Marex Group first reported a position in CRNX in Q1 2026 and has held it in 2 quarters since. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Marex Group held 9,300 shares of Crinetics Pharmaceuticals worth $348K as of Q2 2026.
  • Marex Group bought 2,797 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $104K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Marex Group's portfolio in Q2 2026, its #809 holding.
  • Marex Group first reported a position in Crinetics Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Marex Group's 13F filing for Q2 2026, filed 14 Aug 2026.